<code id='29A03C93C4'></code><style id='29A03C93C4'></style>
    • <acronym id='29A03C93C4'></acronym>
      <center id='29A03C93C4'><center id='29A03C93C4'><tfoot id='29A03C93C4'></tfoot></center><abbr id='29A03C93C4'><dir id='29A03C93C4'><tfoot id='29A03C93C4'></tfoot><noframes id='29A03C93C4'>

    • <optgroup id='29A03C93C4'><strike id='29A03C93C4'><sup id='29A03C93C4'></sup></strike><code id='29A03C93C4'></code></optgroup>
        1. <b id='29A03C93C4'><label id='29A03C93C4'><select id='29A03C93C4'><dt id='29A03C93C4'><span id='29A03C93C4'></span></dt></select></label></b><u id='29A03C93C4'></u>
          <i id='29A03C93C4'><strike id='29A03C93C4'><tt id='29A03C93C4'><pre id='29A03C93C4'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:explore    Page View:41624
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In